# Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
**Date:** 2026-02-23 10:00:00
**Company:** Pfizer Inc.
**Ticker:** PFE
**Source URL:** https://www.businesswire.com/news/home/20260223942896/en/Pfizer-Invites-Public-to-Listen-to-Webcast-of-Pfizer-Discussion-at-Healthcare-Conference/
---
Feb 23, 2026 10:00 AM Eastern Standard Time
# **Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference**
Share
* * *
NEW YORK--( [BUSINESS WIRE](https://www.businesswire.com/))--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST.
To listen to the webcast, visit our web site at [www.pfizer.com/investors](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.pfizer.com%2Finvestors&esheet=54429799&newsitemid=...
# Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
**Date:** 2026-02-23 10:00:00
**Company:** Pfizer Inc.
**Ticker:** PFE
**Source URL:** https://www.businesswire.com/news/home/20260223942896/en/Pfizer-Invites-Public-to-Listen-to-Webcast-of-Pfizer-Discussion-at-Healthcare-Conference/
---
Feb 23, 2026 10:00 AM Eastern Standard Time
# **Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference**
Share
* * *
NEW YORK--( [BUSINESS WIRE](https://www.businesswire.com/))--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST.
To listen to the webcast, visit our web site at [www.pfizer.com/investors](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.pfizer.com%2Finvestors&esheet=54429799&newsitemid=20260223942896&lan=en-US&anchor=www.pfizer.com%2Finvestors&index=1&md5=0f262fc80e36fefdbecd72e094c66f08). Information on accessing and registering for the webcast will be available at [www.pfizer.com/investors](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.pfizer.com%2Finvestors&esheet=54429799&newsitemid=20260223942896&lan=en-US&anchor=www.pfizer.com%2Finvestors&index=2&md5=eb93b7052794bdd40eff81795fc434fc) beginning today.
The transcript and webcast replay of the discussion will be made available on our web site at [www.pfizer.com/investors](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.pfizer.com%2Finvestors&esheet=54429799&newsitemid=20260223942896&lan=en-US&anchor=www.pfizer.com%2Finvestors&index=3&md5=6b448e0ee1b8e2895a89b9130aed6e01) within 24 hours after the end of the live discussion and will be accessible for at least 90 days.
**_About Pfizer: Breakthroughs That Change Patients’ Lives_** At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at [www.Pfizer.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.pfizer.com%2F&esheet=54429799&newsitemid=20260223942896&lan=en-US&anchor=www.Pfizer.com&index=4&md5=d0a0dc7963889a22ee64c87f8654af86). In addition, to learn more, please visit us on [www.Pfizer.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.pfizer.com%2F&esheet=54429799&newsitemid=20260223942896&lan=en-US&anchor=www.Pfizer.com&index=5&md5=c59a2b4d55d30dfe54f483759ef2797c) and follow us on X at [@Pfizer](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2Fpfizer&esheet=54429799&newsitemid=20260223942896&lan=en-US&anchor=%40Pfizer&index=6&md5=df2d16694dc2faab5427f3164f94a776) and [@Pfizer News](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2Fpfizer_news&esheet=54429799&newsitemid=20260223942896&lan=en-US&anchor=%40Pfizer+News&index=7&md5=557857b065ee4e6c7c7317b898df91d5), [LinkedIn](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fpfizer&esheet=54429799&newsitemid=20260223942896&lan=en-US&anchor=LinkedIn&index=8&md5=2bf2e373164b982e901c630b79dd302e), [YouTube](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.com%2Fpfizer&esheet=54429799&newsitemid=20260223942896&lan=en-US&anchor=YouTube&index=9&md5=58b8d265274c71557ab0b3e46bcd6118) and like us on Facebook at [Facebook.com/Pfizer](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FPfizer%2F&esheet=54429799&newsitemid=20260223942896&lan=en-US&anchor=Facebook.com%2FPfizer&index=10&md5=de476b838b9be500978efd8b248c2a38).
**_Disclosure Notice:_** _The webcast may include forward-looking statements about, among other things, our anticipated operating and financial performance, including financial guidance and projections, reorganizations, business plans, strategy, goals and prospects; expectations for our product pipeline (including products from completed or anticipated acquisitions), in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution and projections, pricing and reimbursement, market dynamics, including demand, market size and utilization rates and growth, performance, timing and duration of exclusivity and potential benefits; the impact and potential impact of tariffs and pricing dynamics; strategic reviews; leverage capital allocation objectives; dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities; and our ability to successfully capitalize on growth opportunities and prospects; expectations regarding manufacturing and product supply; our expectations regarding the impact of COVID-19 on our business, operations and financial results; expectations regarding the impact of or changes to existing or new government regulations, laws or executive orders; the expected seasonality of demand for certain of our products and other statements about our business, operations and financial results, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. A description of these risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at_ [_www.sec.gov_](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=54429799&newsitemid=20260223942896&lan=en-US&anchor=www.sec.gov&index=11&md5=ec44fbfb2ff6fc62b1163c29ba144f41) _and_ [_www.pfizer.com_](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.pfizer.com&esheet=54429799&newsitemid=20260223942896&lan=en-US&anchor=www.pfizer.com&index=12&md5=2958b5dd2cb8a7778d2a3a3b488e9790) _._
_The forward-looking statements in the webcast speak only as of the original date of the webcast. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments._
Category: Financial
## Contacts
Media Contact:
[PfizerMediaRelations@Pfizer.com](mailto:PfizerMediaRelations@Pfizer.com)
Investor Contact:
[IR@Pfizer.com](mailto:IR@Pfizer.com)
Industry:
- [Science](https://www.businesswire.com/newsroom?industry=1050101)
- [Other Science](https://www.businesswire.com/newsroom?industry=1050086)
- [Biotechnology](https://www.businesswire.com/newsroom?industry=1000039)
- [Research](https://www.businesswire.com/newsroom?industry=1000159)
- [Pharmaceutical](https://www.businesswire.com/newsroom?industry=1000146)
- [Health](https://www.businesswire.com/newsroom?industry=1000088)
- [Infectious Diseases](https://www.businesswire.com/newsroom?industry=1000096)
- [Clinical Trials](https://www.businesswire.com/newsroom?industry=1000045)
[](https://www.pfizer.com/)
### Pfizer Inc.
NYSE:PFE
* * *
Release Versions
[English](https://www.businesswire.com/news/home/20260223942896/en/Pfizer-Invites-Public-to-Listen-to-Webcast-of-Pfizer-Discussion-at-Healthcare-Conference)
* * *
### Contacts
Media Contact:
[PfizerMediaRelations@Pfizer.com](mailto:PfizerMediaRelations@Pfizer.com)
Investor Contact:
[IR@Pfizer.com](mailto:IR@Pfizer.com)
More News From Pfizer Inc.
Get RSS Feed
[**PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer**](https://www.businesswire.com/news/home/20260227998629/en/PADCEV-Keytruda-Cuts-Risk-of-Recurrence-or-Death-by-Nearly-50-in-Cisplatin-Eligible-Muscle-Invasive-Bladder-Cancer)
NEW YORK & TOKYO--( [BUSINESS WIRE](https://www.businesswire.com/))--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEVTM (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor, in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. Perioperative...
[**U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer**](https://www.businesswire.com/news/home/20260220877238/en/U.S.-FDA-Grants-Full-Approval-to-Pfizers-BRAFTOVI-Combination-Regimen-in-First-Line-Metastatic-Colorectal-Cancer)
NEW YORK--( [BUSINESS WIRE](https://www.businesswire.com/))--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation based on results from the global Phase 3 BREAKWATER trial (NCT04607421). BRAFTOVI in combination with cetuximab and mFOLFOX6 was granted...
[**Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer**](https://www.businesswire.com/news/home/20260217508407/en/Pfizers-BRAFTOVI-Regimen-Improves-Progression-Free-Survival-in-Metastatic-Colorectal-Cancer)
NEW YORK--( [BUSINESS WIRE](https://www.businesswire.com/))--Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. The BRAFTOVI regimen demonstrated a statistically sig...
[Back to Newsroom](https://www.businesswire.com/newsroom)
[](https://www.pfizer.com/)
### Pfizer Inc.
NYSE:PFE
* * *
Release Versions
[English](https://www.businesswire.com/news/home/20260223942896/en/Pfizer-Invites-Public-to-Listen-to-Webcast-of-Pfizer-Discussion-at-Healthcare-Conference)
* * *
### Contacts
Media Contact:
[PfizerMediaRelations@Pfizer.com](mailto:PfizerMediaRelations@Pfizer.com)
Investor Contact:
[IR@Pfizer.com](mailto:IR@Pfizer.com)
## Wish your news had this kind of reach?
[Sign Up](https://www.businesswire.com/sign-up/account) [Learn About Business Wire](https://www.businesswire.com/why-business-wire)